Home / Health / Hope for Addiction: First Patient Dosed in New Trial
Hope for Addiction: First Patient Dosed in New Trial
30 Apr
Summary
- First patient dosed in Phase Ib trial for alcohol use disorder.
- NTX-2001, a partial TAAR1 agonist, is being evaluated for AUD.
- Study involves collaboration with Yale School of Medicine.
Newleos Therapeutics has initiated its Phase Ib clinical study, dosing the first participant for NTX-2001, a novel treatment for alcohol use disorder (AUD). This double-blind, placebo-controlled trial is being conducted in collaboration with Yale School of Medicine.
The study aims to evaluate NTX-2001's effectiveness in reducing alcohol consumption and cravings, alongside its safety and tolerability profile. These evaluations follow extensive preclinical and clinical data supporting the TAAR1 mechanism and NTX-2001's potential. Previous studies involving approximately 645 participants have consistently found NTX-2001 to be safe and well-tolerated.
NTX-2001 is a selective partial agonist of TAAR1, a receptor involved in brain regions that regulate reward pathways. This proof-of-concept study in the US utilizes an alcohol drinking paradigm to model drinking behavior and assess the drug's pharmacokinetics. Successful outcomes could pave the way for treating a wider range of addictive disorders.
